BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Sichuan Kelun-Biotech Gets Green Light for First Radionuclide-Drug Conjugate Clinical Trial

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the invest...

March 26, 2025 | News

China’s Everest Gets FDA Clearance for First mRNA Cancer Vaccine EVM14

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer ...

March 25, 2025 | News

China’s Innovent Doses First Patient in Phase 3 Trial of HER2-Targeted ADC for Ovarian Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

March 25, 2025 | Report

China’s AIM Vaccine Gets FDA Nod for mRNA Shingles Vaccine Trial

AIM Vaccine Co., developed mRNA shingles vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration (FDA). As o...

March 25, 2025 | News

CStone Submits EMA Application to Expand Sugemalimab Use in Stage III Lung Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submiss...

March 25, 2025 | News

Shanghai ArkBio Completes Phase III Trial of AK0901 for Pediatric ADHD in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of a...

March 25, 2025 | News

SineuGene Therapeutics Receives FDA IND Clearance for First-in-Class ALS Gene Therapy SNUG01

SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, announce...

March 25, 2025 | News

Ractigen Reports Promising Phase I Data for First-in-Class saRNA Therapy RAG-01 in Bladder Cancer

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, announced the presentation of...

March 25, 2025 | News

Sungen Biomedical Secures FDA Fast Track Designation for AMI Drug Candidate SGC001

Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Designa...

March 25, 2025 | News

Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer

Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...

March 24, 2025 | Report

Harbour BioMed and AstraZeneca Announce $4.6B Global Collaboration on Next-Gen Multi-Specific Antibodies

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody...

March 24, 2025 | News

Syneron Bio Enters $3.5B Strategic Collaboration with AstraZeneca to Develop Novel Macrocyclic Peptide Therapies

Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical lead...

March 24, 2025 | News

Shanghai Moyom’s Aphranel® MagiCCrystal Becomes First NMPA-Approved CaHA Filler in China

Shanghai Moyom Biotechnology's high-profile brand, Aphranel® MagiCCrystal CaHA Filler, has officially obtained Class III Medical Device ...

March 24, 2025 | Regulatory

Dizal to Present New Findings on Golidocitinib-PD-1 Combo and Sunvozertinib-Anlotinib Therapy at ELCC 2025

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced ...

March 21, 2025 | News

Stay Connected